<DOC>
	<DOCNO>NCT01220180</DOCNO>
	<brief_summary>This study collect post-marketing safety efficacy surveillance data real world clinical use pregabalin approve indication Korea .</brief_summary>
	<brief_title>Lyrica ( Pregabalin ) Korean Post Marketing Surveillance Study</brief_title>
	<detailed_description>continuous patient target disorder collaborate institution</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Any patient treat pregabalin approve indication Korean Food Drug Administration Nonconsenting Hypersensitivity active substance excipients galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>fibromyalgia</keyword>
	<keyword>post-market surveillance</keyword>
	<keyword>prospective observational</keyword>
</DOC>